aguix
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02820454)
Timeline
Indications
Mechanism of action
- Unspecified targetContrast agent
contrast agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aguix
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04789486 | Phase 1/Phase 2 (Phase 2) | May 27, 2021 | Harvard University, NH TherAguix SAS |
| NCT04094077 | Phase 2 | Oct 31, 2019 | Centre Leon Berard |
| NCT03818386 | Phase 2 | Mar 26, 2019 | NH TherAguix SAS, University of Grenoble |
| NCT02820454 | Phase 1 | Jun 1, 2016 | NH TherAguix SAS, University of Grenoble |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NH TherAguix SAS | For profit | 3 | 0 | 2 | 2016 |
| University of Grenoble | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Centre Leon Berard | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1